 |
|
 |
Novartis AG
P.O. Box
CH 4002 Basel
|
|
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Basel, January 31, 2025
|
|
|
Re:
|
Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934
|
|
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby
provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on January 31, 2025.
Respectfully submitted,
Novartis AG
|
|
|
/s/ Karen L. Hale
|
/s/ Harry Kirsch
|
|
|
|
Karen L. Hale
Chief Legal Officer of Novartis |
|
Harry Kirsch
Chief Financial Officer of Novartis |
|